BACKGROUND: We examined the influenza vaccine effectiveness (VE) during the 2013-2014 influenza season, in which 2009 pandemic influenza A(H1N1) virus (influenza A[H1N1]pdm09) predominated. In 2 previous years when influenza A(H3N2) virus predominated, the VE was low and negatively affected by prior year vaccination. METHODS: We enrolled and followed 232 households with 1049 members, including 618 children; specimens were collected from subjects with acute respiratory illnesses. The VE in preventing laboratory-confirmed influenza A(H1N1)pdm09 infection was estimated in adjusted models. Preseason hemagglutination-inhibition and neuraminidase-inhibition antibody titers were determined to assess susceptibility. RESULTS: Influenza A(H1N1)pdm09 was identified in 25 households (10.8%) and 47 individuals (4.5%). Adjusted VE against infection with influenza A(H1N1)pdm09 was 66% (95% confidence interval [CI], 23%-85%), with similar point estimates in children and adults, and against both community-acquired and household-acquired infections. VE did not appear to be different for live-attenuated and inactivated vaccines among children aged 2-8 years, although numbers were small. VE was similar for subjects vaccinated in both current and prior seasons and for those vaccinated in the current season only; susceptibility titers were consistent with this observation. CONCLUSIONS: Findings, including substantial significant VE and a lack of a negative effect of repeated vaccination on VE, were in contrast to those seen in prior seasons in which influenza A(H3N2) virus predominated.
BACKGROUND: We examined the influenza vaccine effectiveness (VE) during the 2013-2014 influenza season, in which 2009 pandemic influenza A(H1N1) virus (influenza A[H1N1]pdm09) predominated. In 2 previous years when influenza A(H3N2) virus predominated, the VE was low and negatively affected by prior year vaccination. METHODS: We enrolled and followed 232 households with 1049 members, including 618 children; specimens were collected from subjects with acute respiratory illnesses. The VE in preventing laboratory-confirmed influenza A(H1N1)pdm09 infection was estimated in adjusted models. Preseason hemagglutination-inhibition and neuraminidase-inhibition antibody titers were determined to assess susceptibility. RESULTS: Influenza A(H1N1)pdm09 was identified in 25 households (10.8%) and 47 individuals (4.5%). Adjusted VE against infection with influenza A(H1N1)pdm09 was 66% (95% confidence interval [CI], 23%-85%), with similar point estimates in children and adults, and against both community-acquired and household-acquired infections. VE did not appear to be different for live-attenuated and inactivated vaccines among children aged 2-8 years, although numbers were small. VE was similar for subjects vaccinated in both current and prior seasons and for those vaccinated in the current season only; susceptibility titers were consistent with this observation. CONCLUSIONS: Findings, including substantial significant VE and a lack of a negative effect of repeated vaccination on VE, were in contrast to those seen in prior seasons in which influenza A(H3N2) virus predominated.
Authors: Suzanne E Ohmit; Joshua G Petrie; Ryan E Malosh; Benjamin J Cowling; Mark G Thompson; David K Shay; Arnold S Monto Journal: Clin Infect Dis Date: 2013-02-14 Impact factor: 9.079
Authors: Robert B Belshe; Kathryn M Edwards; Timo Vesikari; Steven V Black; Robert E Walker; Micki Hultquist; George Kemble; Edward M Connor Journal: N Engl J Med Date: 2007-02-15 Impact factor: 91.245
Authors: Suzanne E Ohmit; Joshua G Petrie; Rachel T Cross; Emileigh Johnson; Arnold S Monto Journal: J Infect Dis Date: 2011-10-12 Impact factor: 5.226
Authors: Colin A Russell; Terry C Jones; Ian G Barr; Nancy J Cox; Rebecca J Garten; Vicky Gregory; Ian D Gust; Alan W Hampson; Alan J Hay; Aeron C Hurt; Jan C de Jong; Anne Kelso; Alexander I Klimov; Tsutomu Kageyama; Naomi Komadina; Alan S Lapedes; Yi P Lin; Ana Mosterin; Masatsugu Obuchi; Takato Odagiri; Albert D M E Osterhaus; Guus F Rimmelzwaan; Michael W Shaw; Eugene Skepner; Klaus Stohr; Masato Tashiro; Ron A M Fouchier; Derek J Smith Journal: Vaccine Date: 2008-09-12 Impact factor: 3.641
Authors: John J Treanor; H Keipp Talbot; Suzanne E Ohmit; Laura A Coleman; Mark G Thompson; Po-Yung Cheng; Joshua G Petrie; Geraldine Lofthus; Jennifer K Meece; John V Williams; Lashondra Berman; Caroline Breese Hall; Arnold S Monto; Marie R Griffin; Edward Belongia; David K Shay Journal: Clin Infect Dis Date: 2012-07-25 Impact factor: 9.079
Authors: Marie R Griffin; Arnold S Monto; Edward A Belongia; John J Treanor; Qingxia Chen; Jufu Chen; H Keipp Talbot; Suzanne E Ohmit; Laura A Coleman; Gerry Lofthus; Joshua G Petrie; Jennifer K Meece; Caroline Breese Hall; John V Williams; Paul Gargiullo; LaShondra Berman; David K Shay Journal: PLoS One Date: 2011-08-12 Impact factor: 3.240
Authors: William W Thompson; Eric Weintraub; Praveen Dhankhar; Po-Yung Cheng; Lynnette Brammer; Martin I Meltzer; Joseph S Bresee; David K Shay Journal: Influenza Other Respir Viruses Date: 2009-01 Impact factor: 4.380
Authors: Joshua G Petrie; Marisa C Eisenberg; Sophia Ng; Ryan E Malosh; Kyu Han Lee; Suzanne E Ohmit; Arnold S Monto Journal: Am J Epidemiol Date: 2017-12-15 Impact factor: 4.897
Authors: Andrew L Valesano; William J Fitzsimmons; John T McCrone; Joshua G Petrie; Arnold S Monto; Emily T Martin; Adam S Lauring Journal: J Virol Date: 2020-02-14 Impact factor: 5.103
Authors: Sarah A Buchan; Stephanie Booth; Allison N Scott; Kimberley A Simmonds; Lawrence W Svenson; Steven J Drews; Margaret L Russell; Natasha S Crowcroft; Mark Loeb; Bryna F Warshawsky; Jeffrey C Kwong Journal: JAMA Pediatr Date: 2018-09-04 Impact factor: 16.193
Authors: Huong Q McLean; Herve Caspard; Marie R Griffin; Manjusha Gaglani; Timothy R Peters; Katherine A Poehling; Christopher S Ambrose; Edward A Belongia Journal: JAMA Netw Open Date: 2018-10-05